Many types of HBV entry inhibitors targeting NTCP-mediated viral infection have been identified to date, including bile acids and their derivatives, peptides, chemical compounds, and neutralizing antibodies (Table 1). The gene discussed is SLC10A1; the disease is viral infectious disease.